Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial

医学 阿帕蒂尼 内科学 临床终点 不利影响 耐火材料(行星科学) 临床试验 临床研究阶段 实体瘤疗效评价标准 胃肠病学 肿瘤科 代理终结点 外科 无进展生存期 危险系数 意向治疗分析 加药 进行性疾病 完全响应 癌症 传统PCI 贝伐单抗 随机对照试验 总体生存率 中止 存活率 免疫疗法 泌尿科 生活质量(医疗保健) 置信区间
作者
Cheng Yang,Qi Jia,Chenglong Zhao,Xinghai Yang,Haifeng Wei,Tielong Liu,Jian Jiao,Zhipeng Wu,Jian Zhao,Wei Xu,Zhenhua Zhou,Wei Wan,Weiwei Zou,Zhi Zhu,Xiaomei Ma,Qi Chen,Wei Guo,Dongqing Zhu,Tao Tan,Yan Lou
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (19): 1822-1832 被引量:3
标识
DOI:10.1200/jco-25-02719
摘要

PURPOSE Limited efficacy of current treatments for chordoma calls for novel therapeutic options. Combination of immune checkpoint inhibitors and antiangiogenic drugs has altered the landscape of cancer treatment but has rarely been investigated in chordoma. METHODS An investigator-initiated, single-center, phase II trial was conducted on camrelizumab (a PD-1 inhibitor, 200 mg once every 2 weeks) plus apatinib (an antiangiogenic drug, 250 mg and 500 mg on alternate days, that is, 250 mg one day, 500 mg the next day, alternating) in patients with refractory chordoma for 4-week cycles. The primary end point was the objective response rate (ORR) per RECIST version 1.1. Secondary end points included ORR per Choi criteria, progression-free survival (PFS), overall survival, the disease control rate, median duration of response (mDoR), safety, and quality of life. The trial is registered with Chictr.org.cn (ChiCTR2100042938). RESULTS Of the 38 patients initially screened between September 2021 and October 2024, 33 were enrolled. Median follow-up duration was 20.8 months (IQR, 13.35-26.55). ORR was 24.2% (8/33 [95% CI, 11.1 to 42.3]) per RECIST 1.1 and 48.5% (16/33 [95% CI, 30.8 to 66.5]) per Choi criteria. The median PFS was 28.4 months (95% CI, 13.53 to 43.28). The mDoR was not reached per RECIST 1.1 and was 22.2 months (95% CI, 12.5 to not reached) per Choi criteria. CDKN2A copy-number deletion or homozygous deletion was found to associate with worse prognosis. The most common grade 3 or 4 treatment-related adverse events included increased aspartate aminotransferase (13 [39.4%]) and increased alanine aminotransferase (11 [33.3%]). No treatment-related deaths occurred. CONCLUSION Combination of camrelizumab and apatinib offered encouraging efficacy with manageable toxicity in chordoma treatment. CDKN2A alterations are associated with worse prognosis and may prove to be a potential biomarker for treatment selection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭映梦完成签到 ,获得积分10
刚刚
小小酥被卷了完成签到,获得积分10
1秒前
科研通AI6.4的应助被obito采纳,获得10
3秒前
天真酸奶的应助被obito采纳,获得10
3秒前
CipherSage的应助被明亮绮菱采纳,获得10
3秒前
王明月发布了新的文献求助10
3秒前
Gyqqqq完成签到,获得积分10
4秒前
Owen的应助被feisun采纳,获得10
5秒前
5秒前
难过含烟完成签到 ,获得积分10
6秒前
likun完成签到,获得积分10
6秒前
7秒前
8秒前
科研通AI2S的应助被liquss采纳,获得10
8秒前
王木木要努力完成签到,获得积分10
8秒前
漫漫发布了新的文献求助10
8秒前
说谎的桔梗花完成签到,获得积分10
10秒前
10秒前
田様的应助被辛勤的振家采纳,获得10
11秒前
MARIO发布了新的文献求助10
12秒前
maoqiuzhao完成签到,获得积分10
12秒前
13秒前
充电宝的应助被庐州月采纳,获得10
13秒前
15秒前
XCZ_UHANGHI完成签到 ,获得积分10
16秒前
CodeCraft的应助被MADAO采纳,获得30
16秒前
16秒前
17秒前
18秒前
Tuniverse_发布了新的文献求助10
18秒前
lx的应助被科研通管家采纳,获得20
18秒前
18秒前
团子完成签到 ,获得积分10
19秒前
小蘑菇的应助被科研通管家采纳,获得10
19秒前
白敬亭发布了新的文献求助10
19秒前
coolru的应助被科研通管家采纳,获得10
19秒前
19秒前
共享精神的应助被科研通管家采纳,获得10
19秒前
Owen的应助被科研通管家采纳,获得10
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621